Investor Presentation: First Nine Months of 2020
83
Investor presentation
First nine months of 2020
EMEA at a glance
Novo Nordisk®
Million
Diabetes trend
Diabetes market by value and Novo
Nordisk market share
Novo Nordisk reported sales
250
DKK
billion
31%
100
First nine months
2020
Sales
(mDKK)
Growth²
80%
Long-acting insulin³
4,916
12%
I
200
28%
I
J
Premix insulin4
2,275
(1%)
80
GLP-1
60%
Fast-acting insulin
4,968
6%
27%1
150
Human insulin
223
100
40
171
60
40
1,823
0%
60
Total insulin
4%1
Insulin
13,982
6%
40%
GLP-16
5,547
35%
Other Diabetes care?
547
(31%)
134
50
20
OAD 20%
Diabetes care
20,076
11%
20
11%1
Obesity care
834
8%
(SaxendaⓇ)
0
2019
0
0%
2030
2045
Aug
2015
Aug
2020
Diabetes & Obesity
20,910
11%
care
Population with diabetes
Diabetes growth rate
Biopharm³
5,249
10%
GLP-1 MS
-Insulin MS
-OAD MS
Total
26,159
11%
Diabetes trend estimates based on the following International Diabetes Foundation
defined regions: Africa, Europe, Middle East and North Africa, South and Central
America, South East Asia and Western Pacific Source: International Diabetes
Federation: Diabetes Atlas 1th Edition 2000 and Diabetes Atlas 9th Edition 2019;
EMEA: Europe, Middle East and Africa
1 CAGR calculated for 5-year period; Competitor insulin value market shares, as of Aug
2020: Novo Nordisk 47%, Sanofi 33% and Eli Lilly 16%; Competitor GLP-1 value market
shares, as of Aug 2020: Novo Nordisk 54%, Eli Lilly 41% and AstraZeneca 5%; OAD: Oral
anti-diabetic; MS: Market share; Source: IQVIA MAT, Aug 2020 value figures
2 At constant exchange rates; 3 Comprises TresibaⓇ, XultophyⓇ and LevemirⓇ: 4
Comprises RyzodegⓇ and NovoMix®; 5 Comprises FiaspⓇ and NovoRapidⓇ;
Comprises VictozaⓇ and Ozempic®: 7 Comprises Novo NormⓇ and needles; 8
Comprises primarily NovoSeven®, Novo Eight®, NovoThirteen, Refixia®,
Norditropin®, Vagifem® and Activelle®View entire presentation